Chronic Respiratory Disease Participant Engagement Study

NCT07924462 · tracked via the Priya Life Science UK tracker

Sponsor

Richmond Research Institute

Phase

Observational

Started

2026-11

Last updated

2026-11-09

Condition(s) studied

Interstitial Lung Disease (ILD)Chronic Respiratory DiseasesAlpha-1 Antitrypsin Deficiency (AATD)Chronic Obstructive Pulmonary Disease (COPD)AsthmaBronchiectasis

Study summary

This study is designed for adults who have, or suspected to have, a long-term respiratory (lung) condition such as Alpha-1 Antitrypsin Deficiency (AATD), chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, or interstitial lung disease (ILD).

The aim of the study is to help participants become familiar with the clinical trials unit environment and research team before deciding whether they would like to take part in future clinical trials.

Participants will attend a study visit at the clinical trials unit, where they will receive a guided tour of the facilities and undergo a range of routine health assessments. These may include a review of their medical history, measurements of height, weight, blood pressure and oxygen levels, breathing tests, blood tests, heart tracing (ECG), liver assessment, and questionnaires about their symptoms and quality of life. Some participants may also undergo genetic testing if it is clinically appropriate and previous results are not available.

The information collected will help establish a clinical baseline and improve understanding of how respiratory diseases affect people in everyday life. The study will also explore how symptoms and quality of life relate to clinical measurements and other health information.

Participants will be contacted after their visit to discuss any clinically relevant findings and to answer any questions they may have. If a previously unrecognised condition is identified, participants will be advised appropriately and, with their consent, their GP may be informed to support any further care that may be needed.

The findings from this study may help improve the design of future clinical trials and support the development of more patient-centred research.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Male or female participants aged ≥ 18 years at the date of signing the PIS/ICF. 2. Ability to provide written, personally signed, and dated informed consent in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines E6 (R3) (2025) and applicable regulations, before any study-specific procedures are performed. 3. Diagnosis with or suspicion of chronic respiratory disease including but not limited to: AATD, COPD, Asthma, Bronchiectasis, ILD and any other chronic respiratory diseases considered appropriate by the Investigator and Sponsor Exclusion Criteria: 1. Unwilling or unable to comply with the protocol-defined study assessments. 2. Any other significant disease or disorder that, in the opinion of the Principal Investigator (PI) or Sponsor, may either place the participant at risk from participation, or influence the clinical baseline

Primary outcome measure(s)

Number of patients indicating willingness to be re-contacted for future clinical trials — Until the end of the study (up to 5 weeks)]
Participation feedback questionnaire results using Participant Feedback and Clinical Research Experience Questionnaire — Until the end of the study (up to 5 weeks)]

Trial sites (1)

Facility	City	Region	Status
Richmond Pharmacology Limited	London	United Kingdom	Recruiting

More Richmond Research Institute trials in the UK

PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY Recruiting

Serological and PCR Testing for COVID-19 Recruiting

Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care Recruiting

Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease Recruiting

Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations Recruiting

Other trials for the same condition

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma Active, not recruiting

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma Active, not recruiting

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma Recruiting

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma Active, not recruiting

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07924462 on ClinicalTrials.gov ↗ ← All trials in the UK